Literature DB >> 15595334

Fibroblast growth factor 23, parathyroid hormone, and 1alpha,25-dihydroxyvitamin D in surgically treated primary hyperparathyroidism.

Peter J Tebben1, Ravinder J Singh, Bart L Clarke, Rajiv Kumar.   

Abstract

OBJECTIVE: To determine whether fibroblast growth factor 23 (FGF23) contributes to the hypophosphatemia of primary hyperparathyroldism. PATIENTS AND METHODS: Thirteen adult patients with primary hyperparathyroidism had serum collected before and after parathyroidectomy for analysis of inorganic phosphorus, calcium, 1alpha,25-dihydroxyvitamin D (1alpha,25[OH]2D), parathyroid hormone (PTH), FGF23, creatinine, and bone-specific alkaline phosphatase (BSAP). Patients were recruited between July 24, 2003, and February 11, 2004.
RESULTS: Before surgery, patients had elevated serum calcium and PTH concentrations. Serum phosphorus concentrations were in the low-normal range. The FGF23 concentrations were not elevated in patients with primary hyperparathyroidism compared with healthy controls. Within 24 hours of surgery, serum calcium, PTH, 1alpha,25(OH)2D, and BSAP concentrations were lower (P < .002 for all) and phosphorus concentrations were higher (P = .003) than in the preoperative state. The FGF23 concentrations were similar 1 day and 6 weeks after surgery. The FGF23 concentrations did not correlate with serum phosphorus, calcium, PTH, 1alpha,25(OH)2D, creatinine, or BSAP concentrations in the preoperative or postoperative state.
CONCLUSION: Parathyroid hormone is the major regulator of serum phosphorus concentrations in patients with primary hyperparathyroidism. Fibroblast growth factor 23 does not appear to play a role in phosphorus homeostasis in patients with surgically treated primary hyperparathyroidism.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15595334     DOI: 10.4065/79.12.1508

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  16 in total

Review 1.  Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism.

Authors:  L Darryl Quarles
Journal:  Nat Rev Endocrinol       Date:  2012-01-17       Impact factor: 43.330

2.  Effects of gonadal steroid withdrawal on serum phosphate and FGF-23 levels in men.

Authors:  Sherri-Ann M Burnett-Bowie; Natalia Mendoza; Benjamin Z Leder
Journal:  Bone       Date:  2006-12-08       Impact factor: 4.398

Review 3.  Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease.

Authors:  L Darryl Quarles
Journal:  Exp Cell Res       Date:  2012-03-07       Impact factor: 3.905

Review 4.  The PTH-Vitamin D-FGF23 axis.

Authors:  Jenny E Blau; Michael T Collins
Journal:  Rev Endocr Metab Disord       Date:  2015-06       Impact factor: 6.514

Review 5.  FGF23: its role in renal bone disease.

Authors:  Masafumi Fukagawa; Junichiro James Kazama
Journal:  Pediatr Nephrol       Date:  2006-08-24       Impact factor: 3.714

Review 6.  Evidence for FGF23 involvement in a bone-kidney axis regulating bone mineralization and systemic phosphate and vitamin D homeostasis.

Authors:  Aline Martin; L Darryl Quarles
Journal:  Adv Exp Med Biol       Date:  2012       Impact factor: 2.622

Review 7.  DIAGNOSIS OF ENDOCRINE DISEASE: Mosaic disorders of FGF23 excess: Fibrous dysplasia/McCune-Albright syndrome and cutaneous skeletal hypophosphatemia syndrome.

Authors:  Luis F de Castro; Diana Ovejero; Alison M Boyce
Journal:  Eur J Endocrinol       Date:  2020-05       Impact factor: 6.664

Review 8.  FGF-23 and secondary hyperparathyroidism in chronic kidney disease.

Authors:  Justin Silver; Tally Naveh-Many
Journal:  Nat Rev Nephrol       Date:  2013-07-23       Impact factor: 28.314

Review 9.  Fibroblast growth factor 23: state of the field and future directions.

Authors:  Nisan Bhattacharyya; William H Chong; Rachel I Gafni; Michael T Collins
Journal:  Trends Endocrinol Metab       Date:  2012-08-24       Impact factor: 12.015

Review 10.  A systems biology preview of the relationships between mineral and metabolic complications in chronic kidney disease.

Authors:  L Darryl Quarles
Journal:  Semin Nephrol       Date:  2013-03       Impact factor: 5.299

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.